Bexarotene , ≥99% , 153559-49-0
Synonym(s):
4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid;4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid;Bexarotene - CAS 153559-49-0 - Calbiochem;LGD-1069;SR-11247
| Pack Size | Price | Stock | Quantity |
| 50MG | RMB172.80 | In Stock |
|
| 100mg | RMB399.20 | In Stock |
|
| 250MG | RMB620.80 | In Stock |
|
| 1G | RMB1933.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 230-231°C |
| Boiling point: | 489.7±44.0 °C(Predicted) |
| Density | 1.042 |
| RTECS | DH6834830 |
| storage temp. | -20°C |
| solubility | Soluble in DMSO and ethanol |
| pka | 4.08±0.10(Predicted) |
| form | White powder |
| color | white to beige |
| λmax | 264nm(MeOH)(lit.) |
| Merck | 14,1194 |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 week. |
| InChI | InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26) |
| InChIKey | NAVMQTYZDKMPEU-UHFFFAOYSA-N |
| SMILES | C(O)(=O)C1=CC=C(C(C2=C(C)C=C3C(=C2)C(C)(C)CCC3(C)C)=C)C=C1 |
Description and Uses
Bexarotene was launched in the US for the treatment of manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. The four step synthesis of bexarotene involves a double Friedel-Craft alkylation of toluene with 2,5-dichloro-2,5-dimethylhexane followed by acylation with monomethylterephthalic acid chloride, then Wittig methylidenation. Bexarotene is the first retinoid X receptor (RXR) agonist to be selective versus retinoid A receptors (RAR). Its activation of the three RXRα, β, γ isoforms induces cell differentiation and apoptosis and inhibits cell proliferation in several models of cancer. In phase ll/lll clinical trials, 48% of patients with refractory or persistent early-stage cutaneous T-cell lymphoma achieved a complete or partial response when treated with 300 mg/m2/day of bexarotene. It was shown in phase I trials that this second-generation retinoid was substantially less toxic than the broad-spectrum or RARselective retinoids.
Bexarotene is used as a Synthetic retinoid analog with specific affinity for the retinoid X receptor, an antineoplastic agent, already approved as an oral antineoplastic agent for cutaneous T cell lymphoma and being investigated against other cancers. A study has found that bexarotene in a mouse Alzheimer?s model lowered the most toxic form of β-amyloid peptide and increased cognitive ability.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P280a-P304+P340-P305+P351+P338-P405-P501a |
| WGK Germany | 3 |
| HS Code | 29163990 |
| Hazardous Substances Data | 153559-49-0(Hazardous Substances Data) |
